FDA Brief

Warning letters Drugs

FDA warning letter to

V10Suppliers.com

High riskIssued Jul 22, 2024Posted Jul 23, 2024Center for Drug Evaluation and Research (CDER)

FDA warned UK website V10Suppliers.com for selling unapproved, misbranded opioid drugs to U.S. consumers.

What happened

FDA reviewed the website www.V10Suppliers.com and found it offering opioid prescription drugs, including tramadol and oxycodone, for sale to U.S. consumers. FDA said the products are unapproved new drugs and are misbranded because they are offered without a prescription and lack adequate directions for lay use.

What FDA found

  1. Sold tramadol and oxycodone products that are not FDA-approved new drugs and have no approved applications in effect.

    FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]
  2. Sold prescription opioid drugs with labeling that did not give adequate directions for safe use by a layperson, so they are misbranded.

    FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]
  3. Offered prescription drugs for sale without requiring a prescription, which misbrands them while held for sale.

    FD&C Act sections 503(b)(1) and 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]
  4. Caused misbranded drugs to be introduced into interstate commerce by offering them for sale to U.S. consumers.

    FD&C Act section 301(a) [21 U.S.C. § 331(a)]

What FDA wants

FDA asks V10Suppliers.com to stop offering unapproved and misbranded drugs to U.S. consumers and to respond in writing within 15 working days describing steps taken to fix the violations and prevent recurrence. If it cannot complete corrections in that time, it must state why and give a completion date.

Who should pay attention

  • U.S. consumers who buy medicines online
  • online sellers of prescription opioids to U.S. customers
  • companies that ship, pay for, or advertise online drug sales

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk